US2016271138A1PendingUtilityA1

Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders

65
Assignee: MASSACHUSETTS GEN HOSPITALPriority: Oct 25, 2012Filed: Feb 19, 2016Published: Sep 22, 2016
Est. expiryOct 25, 2032(~6.3 yrs left)· nominal 20-yr term from priority
Inventors:David R. Elmaleh
A61P 43/00A61P 25/28A61P 29/00A61P 17/02A61P 25/00A61K 31/194A61K 31/075A61K 48/00A61K 31/55A61K 31/13A61K 31/435A61K 31/706A61K 45/06A61K 51/0453A61K 39/0005A61K 38/185A61K 31/5415A61K 31/225C07K 16/18A61K 31/438A61K 31/047A61K 31/713A61K 31/353A61K 31/428A61K 31/352A61K 31/192
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of treating a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury. 
     
     
         22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury. 
     
     
         23 . The method of  claim 21 , wherein the first compound and the second compound are associated with Tau or alpha-Synuclein. 
     
     
         24 . The method of  claim 22 , wherein the first compound and the second compound are associated with Tau or alpha-Synuclein. 
     
     
         25 . The method of  claim 23 , wherein the compound associated with Tau or alpha-Synuclein is an inhibitor of tau protein aggregation. 
     
     
         26 . The method of  claim 25 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride. 
     
     
         27 . The method of  claim 24 , wherein the compound associated with Tau or alpha-Synuclein is an inhibitor of tau protein aggregation. 
     
     
         28 . The method of  claim 27 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride.

Join the waitlist — get patent alerts

Track US2016271138A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.